FDA
-
-
-
-
-
-
-
FDA grants priority review to Genentech's Enspryng for thyroid eye disease
-
-
-
-
-
-
-
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
-
-
-
-
-
-
-
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
-
-
-
-
-
-
-
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
-
-
-
-
-
-
-
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
-
-
-
-
-
-
-
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
-
-
-
-
-
-
-
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
-
328,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
